STOCK TITAN

Cytek Biosciences, Inc. - CTKB STOCK NEWS

Welcome to our dedicated page for Cytek Biosciences news (Ticker: CTKB), a resource for investors and traders seeking the latest updates and insights on Cytek Biosciences stock.

Cytek Biosciences, Inc. (CTKB) delivers advanced cell analysis solutions through its patented Full Spectrum Profiling technology, serving research institutions and biotech organizations worldwide. This page provides investors and industry professionals with direct access to official company announcements and relevant news updates.

Discover the latest developments including product innovations, financial results, strategic partnerships, and regulatory milestones. Our curated collection ensures you stay informed about CTKB’s progress in advancing high-resolution cellular analysis tools for scientific research.

Key updates cover earnings reports, technology enhancements, executive leadership changes, and market expansion initiatives. All content is sourced from verified channels to maintain accuracy and compliance with financial disclosure standards.

Bookmark this page for streamlined access to Cytek Biosciences’ evolving story in life sciences innovation. Check back regularly for real-time updates that matter to stakeholders in the biotech investment community.

Rhea-AI Summary
Cytek Biosciences reports strong financial results for Q4 and full year 2023 with revenue growth, new product launches, and strategic agreements. Despite increasing expenses, the company shows positive performance and outlines a growth outlook for 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.9%
Tags
-
Rhea-AI Summary
Cytek Biosciences, Inc. (CTKB) will be participating in several upcoming investor conferences, including the BTIG 11th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference, Raymond James 45th Annual Institutional Investors Conference, and TD Cowen 44th Annual Health Care Conference. The company will be presenting at these events, providing an opportunity for interested parties to access live and archived webcasts of the presentations on the 'Investors' section of the company website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.07%
Tags
conferences
-
Rhea-AI Summary
Cytek Biosciences, Inc. (CTKB) will report financial results for Q4 and full year 2023 on Feb 28, 2024, followed by a webcast conference call to discuss results, business developments, and outlook.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.07%
Tags
conferences earnings
Rhea-AI Summary
Cytek Biosciences, Inc. (Nasdaq: CTKB) has signed an agreement with the Centre for Genomic Regulation (CRG) and the Pompeu Fabra University (UPF) to drive technological innovation and accelerate discoveries for the scientific community. The collaboration aims to develop and test new methods using Cytek's Full Spectrum Profiling technology, providing researchers with continuous training on innovative developments in flow cytometry. Cytek's advanced cell analysis solutions offer a more comprehensive, accurate, and detailed analysis of cellular characteristics, leading to a better understanding of complex biological processes and the development of more effective therapeutic strategies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.53%
Tags
none
-
Rhea-AI Summary
Cytek Biosciences, Inc. (Nasdaq: CTKB) expects its full-year revenue for 2023 to be near the high end of the company’s most recent revenue guidance range of $188 million to $192 million. The preliminary unaudited results were announced ahead of the 42nd Annual J.P. Morgan Healthcare Conference, where CEO Wenbin Jiang is scheduled to present and participate in a Q&A session on January 11, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.29%
Tags
none
-
Rhea-AI Summary
Cytek Biosciences, Inc. (Nasdaq: CTKB) to participate in the 42nd Annual J.P. Morgan Healthcare Conference. CEO Dr. Wenbin Jiang to present and participate in a Q&A session on January 11, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.49%
Tags
conferences
Rhea-AI Summary
Cytek Biosciences, Inc. (Nasdaq: CTKB) introduces Cytek Orion™ reagent cocktail preparation system, saving time and resources, improving efficiency, and accuracy in laboratory workflow. The system simplifies and accelerates the preparation of multicolor antibody cocktails for flow cytometry, accommodating up to 60 individual reagent antibody conjugates. It is instrument-agnostic and seamlessly integrates with Cytek's ecosystem of complete solutions. The system reduces hands-on time, decreases costs due to potential human errors, and minimizes repetitive motion injuries, offering a smaller footprint and cost-effectiveness compared to competitive solutions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.18%
Tags
none
-
Rhea-AI Summary
Cytek Biosciences, Inc. (Nasdaq: CTKB) announced its participation in the Piper Sandler 35th Annual Healthcare Conference in New York. The company's management will engage in a fireside chat on November 28th, accessible through a live and archived webcast on the 'Investors' section of the company website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.39%
Tags
conferences
-
Rhea-AI Summary
Cytek Biosciences, Inc. (Nasdaq: CTKB) announced that its Cytek® Aurora™ CS system won the 'Cell Sorting Product of the Year' award in the BioTech Breakthrough Awards. The system, based on Full Spectrum Profiling™ (FSP™) technology, provides high-performance cell sorting and facilitates the resolution of challenging cell populations. This recognition highlights Cytek's commitment to advancing cell analysis solutions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.36%
Tags
none
Rhea-AI Summary
Cytek Biosciences (CTKB) Reports 19% Revenue Growth in Q3 2023, Achieves ISO 13485 Certification, and Repurchases $9.4M in Shares
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.36%
Tags
Cytek Biosciences, Inc.

Nasdaq:CTKB

CTKB Rankings

CTKB Stock Data

467.56M
116.54M
8.9%
61.33%
2.69%
Medical Devices
Laboratory Analytical Instruments
Link
United States
FREMONT